AJMC Staff

In a late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting, researchers presented an interim analysis of a randomized phase 2 trial of second- or third-line nivolumab, with or without ipilimumab, in patients with second- or third-line malignant pleural mesothelioma.

The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.

In a study performed by the Grupo Español de Investigación en Sarcomas, Fas biomarker detection showed value in predicting progression-free and overall survival after trabectedin administration to patients with advanced soft tissue sarcoma.

An interim analysis of two phase 2 trials, reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting, has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer.

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting reported a significant effect on overall and failure-free survival from the addition of abiraterone at the start of androgen deprivation therapy in men with high-risk prostate cancer.

A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting showed that alectinib demonstrates efficacy and favorable tolerability compared with crizotinib in the primary results of the global phase 3 ALEX study in patients with treatment-naïve advanced anaplastic lymphoma kinase (ALK)-positive non—small cell lung cancer (NSCLC).

ARCHER 1050, the first phase 3 head-to-head study of epithelial growth factor receptor (EGFR) tyrosine kinase inhibition, has produced results that demonstrate statistically significant and clinically meaningful improvement with dacomitinib compared with gefitinib (Iressa) as first-line therapy for non—small cell lung cancer (NSCLC) with EGFR-activating mutations.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

A collaborative research study, based on survey results gathered by the American Cancer Society, has found a correlation between depressive symptoms in cancer caregivers and a decline in their physical health.